“…Therefore, proposed results clearly highlight that the variation of β and of the coating thickness produce some counteracting effects on the DES therapeutic effectiveness: when the therapeutic window (i.e., the duration of the therapeutic action) increases then the reacting drug fraction (i.e., the antiproliferative effectiveness) reduces, and viceversa. Accordingly, fully in agreement with clinical evidence (e.g., [6][7][8][9]12,31,32,55]) and other modeling approaches (e.g., [18][19][20][21][22][23][24][25][26][27][28][29][30][34][35][36]), applicative examples herein discussed suggest that a suitable therapeutic effectiveness can be obtained by choosing coating material and drug type such that drug diffusivity D 1 and topcoat permeability P 1 are small enough, as well as by prescribing values for coating thickness and drug reaction rate within certain optimal ranges.…”